Lessons learned from failed oncology trials in 2010

By Kim Bill on May 8, 2011 | In Drug Development

This is the conclusion from Quintiles White Paper- you can read it from my LINKS tab :))

Importance of expanding phase II trials when a subgroup analysis has generated a hypothesis

Need to have clear preclinical documentation of a possible MOA and of drug interactions

Demonstration of invivo activity

Importance of knowing tumour genomics

Need to define highly predictive biomarkers that will allow targeting of drugs to specific patients who will derive a clinically meaningful benefit

Need to better understand the interactions between tumour genotype and patient biology.

Innovative and well planned trials, involve oncology experts at early stages of clinical development.

ALSA Good Drug Development